<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05107011</url>
  </required_header>
  <id_info>
    <org_study_id>LBL-015-CN-001</org_study_id>
    <nct_id>NCT05107011</nct_id>
  </id_info>
  <brief_title>Phase I/II Clinical Trial of LBL-015 for Injection</brief_title>
  <official_title>An Open-label, Multi-center, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti Tumor Activity of LBL-015 in Patients With Advanced Malignant Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing Leads Biolabs Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing Leads Biolabs Co.,Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase I/II clinical study evaluating LBL-015 in the treatment of subjects with advanced&#xD;
      solid tumors&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is a single-arm, open, multi-center, dose-escalation and extended phase I/II&#xD;
      study, aiming to evaluate the safety, tolerability, pharmacokinetic characteristics, and&#xD;
      receptor occupancy of LBL-015 in patients with advanced malignant tumors Rate (RO),&#xD;
      immunogenicity and effectiveness. Approximately 202 subjects with advanced malignant tumors&#xD;
      are planned to be included.&#xD;
&#xD;
      The study is divided into two phases: Phase I (dose escalation/PK expansion phase) and Phase&#xD;
      II (indication expansion phase)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>28 days after the first dose</time_frame>
    <description>During the dose-escalation phase, the highest dose of dose-limiting toxicity for subjects less than or equal to 1/6 of the study drug within 4 weeks of starting treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-limiting toxicities（DLT)</measure>
    <time_frame>28 days after the first dose</time_frame>
    <description>During the DLT observation period, the subject has an event that is reasonably related to the test drug (possibly, likely or definitely related)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">202</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Evaluation of LBL-015 Phase I/II study in patients with advanced malignancies</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: LBL-015 for Injection The test drugLBL-003will be preset with 5 escalation dose levels: dose A , dose B, dose C ,dose D and dose E, administered twice a week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LBL-015 for Injections</intervention_name>
    <description>LBL-015 was given every two weeks for treatment</description>
    <arm_group_label>Evaluation of LBL-015 Phase I/II study in patients with advanced malignancies</arm_group_label>
    <other_name>LBL-015</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Agree to follow the trial treatment plan and visit plan, join the group voluntarily,&#xD;
             and sign a written informed consent form;&#xD;
&#xD;
          2. Age ≥18 and ≤75 years old at the time of signing the informed consent form, regardless&#xD;
             of gender;&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group performance status scoring criteria (ECOG) PS of 0&#xD;
             ~ 1 points (see Appendix 1 for criteria);&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have received chemotherapy, radiotherapy, biological therapy, endocrine therapy,&#xD;
             immunotherapy and other anti-tumor treatments within 4 weeks before using the study&#xD;
             drug for the first time, except for the following items:&#xD;
&#xD;
          2. Have received other unmarketed clinical research drugs or treatments within 4 weeks&#xD;
             before using the research drug for the first time;&#xD;
&#xD;
          3. Patients who have previously received treatment with PD-1/PD-L1 and TGF-β bifunctional&#xD;
             antibody drugs or received treatment with PD-1/PD-L1 combined with TGF-β target drugs;&#xD;
&#xD;
          4. Patients who have undergone major organ surgery (excluding needle biopsy) or have&#xD;
             significant trauma within 4 weeks before using the study drug for the first time,or&#xD;
             required elective surgery during the trial period;&#xD;
&#xD;
          5. Use of immunomodulatory drugs within 14 days before the first use of study drugs,&#xD;
             including but not limited to thymosin, interleukin-2, interferon, etc.;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin li</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Oriental Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>jingning song</last_name>
    <phone>025-83378099-842</phone>
    <email>songjingning@leadsbiolabs.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ting lv</last_name>
    <phone>025-83378099-842</phone>
    <email>lvting@leadsbiolabs.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Bengbu Medical College</name>
      <address>
        <city>Bengbu</city>
        <state>Anhui</state>
        <zip>233000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>jingning song</last_name>
      <phone>02583378099</phone>
      <email>songjingning@leadsbiolabs.com</email>
    </contact>
    <contact_backup>
      <last_name>ting lv</last_name>
      <phone>02583378099</phone>
      <email>lvting@leadsbiolabs.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>jingning song</last_name>
      <phone>02583378099</phone>
      <email>songjingning@leadsbiolabs.com</email>
    </contact>
    <contact_backup>
      <last_name>ting lv</last_name>
      <phone>02583378099</phone>
      <email>lvting@leadsbiolabs.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410031</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>jingning song</last_name>
      <phone>02583378099</phone>
      <email>songjingning@leadsbiolabs.com</email>
    </contact>
    <contact_backup>
      <last_name>ting lv</last_name>
      <phone>02583378099</phone>
      <email>lvting@leadsbiolabs.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Shandong Cancer Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250117</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>jingning song</last_name>
      <phone>02583378099</phone>
      <email>songjingning@leadsbiolabs.com</email>
    </contact>
    <contact_backup>
      <last_name>ting lv</last_name>
      <phone>02583378099</phone>
      <email>lvting@leadsbiolabs.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Shanghai Oriental Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200123</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>jingning song</last_name>
      <phone>02583378099</phone>
      <email>songjingning@leadsbiolabs.com</email>
    </contact>
    <contact_backup>
      <last_name>ting lv</last_name>
      <phone>02583378099</phone>
      <email>lvting@leadsbiolabs.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 20, 2021</study_first_submitted>
  <study_first_submitted_qc>November 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

